| 1 |
27959426 | 17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib. | 2017 Feb |
1 |
| 2 |
28247504 | Epigallocatechin-3-gallate augments the therapeutic effects of benzo[a]pyrene-mediated lung carcinogenesis. | 2017 Jul 8 |
1 |
| 3 |
26124325 | MMP9, Cyclin D1 and β-Catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro. | 2015 Jul |
2 |
| 4 |
26288223 | Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells. | 2015 |
1 |
| 5 |
23255952 | Transducer of erbB2.1 is a potential cellular target of gefitinib in lung cancer therapy. | 2013 Jan |
2 |
| 6 |
19946741 | Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. | 2010 Sep |
1 |
| 7 |
18803287 | Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib. | 2008 Dec 15 |
1 |
| 8 |
15570011 | Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. | 2004 Nov 15 |
6 |